Back to Search Start Over

Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD–MBD) biomarkers in nephrology practices.

Authors :
Fusaro, Maria
Barbuto, Simona
Gallieni, Maurizio
Cossettini, Althea
Sartò, Giulia Vanessa Re
Cosmai, Laura
Cianciolo, Giuseppe
Manna, Gaetano La
Nickolas, Thomas
Ferrari, Serge
Bover, Jordi
Haarhaus, Mathias
Marino, Carmela
Mereu, Maria Cristina
Ravera, Maura
Plebani, Mario
Zaninotto, Martina
Cozzolino, Mario
Bianchi, Stefano
Messa, Piergiorgio
Source :
Clinical Kidney Journal; Jan2024, Vol. 17 Issue 1, p1-14, 14p
Publication Year :
2024

Abstract

Background Chronic kidney disease mineral bone disorder (CKD-MBD) is a condition characterized by alterations of calcium, phosphate, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF-23) metabolism that in turn promote bone disorders, vascular calcifications, and increase cardiovascular (CV) risk. Nephrologists' awareness of diagnostic, prognostic, and therapeutic tools to manage CKD-MBD plays a primary role in adequately preventing and managing this condition in clinical practice. Methods A national survey (composed of 15 closed questions) was launched to inquire about the use of bone biomarkers in the management of CKD-MBD patients by nephrologists and to gain knowledge about the implementation of guideline recommendations in clinical practice. Results One hundred and six Italian nephrologists participated in the survey for an overall response rate of about 10%. Nephrologists indicated that the laboratories of their hospitals were able to satisfy request of ionized calcium levels, 105 (99.1%) of both PTH and alkaline phosphatase (ALP), 100 (94.3%) of 25(OH)D, and 61 (57.5%) of 1.25(OH)<subscript>2</subscript>D; while most laboratories did not support the requests of biomarkers such as FGF-23 (intact: 88.7% and c-terminal: 93.4%), Klotho (95.3%; soluble form: 97.2%), tartrate-resistant acid phosphatase 5b (TRAP-5b) (92.5%), C-terminal telopeptide (CTX) (71.7%), and pro-collagen type 1 N-terminal pro-peptide (P1NP) (88.7%). As interesting data regarding Italian nephrologists' behavior to start treatment of secondary hyperparathyroidism (sHPT), the majority of clinicians used KDOQI guidelines (n  = 55, 51.9%). In contrast, only 40 nephrologists (37.7%) relied on KDIGO guidelines, which recommended referring to values of PTH between two and nine times the upper limit of the normal range. Conclusion Results point out a marked heterogeneity in the management of CKD-MBD by clinicians as well as a suboptimal implementation of guidelines in Italian clinical practice. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20488505
Volume :
17
Issue :
1
Database :
Complementary Index
Journal :
Clinical Kidney Journal
Publication Type :
Academic Journal
Accession number :
174980026
Full Text :
https://doi.org/10.1093/ckj/sfad290